Navigation Links
Response Genetics, Inc. to Offer ROS1 Testing for Lung Cancer
Date:11/5/2012

LOS ANGELES, Nov. 5, 2012 /PRNewswire/ -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the launch of testing for ROS1 gene rearrangements.  Recently, the Massachusetts General Hospital Cancer Center ("MGH") published studies showing that ROS1 driven tumors are sensitive to the FDA approved drug XALKORI®1 (crizotinib)2 to treat non-small-cell lung cancer ("NSCLC") patients with ALK gene rearrangements.  Tumors driven by rearrangements in the ROS1 gene represent an additional 1 to 2 percent of patients who may be candidates for crizotinib therapy.3 The company will offer both fluorescence in situ hybridization ("FISH") and polymerase chain reaction ("PCR") based ROS1 translocation testing."We are pleased to add ROS1 to our growing test menu," said Thomas Bologna, chairman and CEO of Response Genetics.  "We believe the dual option of FISH and PCR represent a unique offering and is consistent with our Leave No Stone Unturned program whereby we go to great lengths to help patients receive optimal therapy.  While FISH is the technology that has been used for ROS1 to date, PCR has the advantage of providing additional information about the variant found, information that may be useful for evaluating response and resistance mechanisms.
This promising new marker is now readily available to pathologists and oncologists seeking fast turnaround time and utilizes the company's proprietary methods that enable results on very small biopsies including fine needle aspirates."

ROS1 supplements the company's recently introduced Leave No Stone Unturned program, in which patients whose tumors test negative for the ALK Break Apart FISH assay receive follow-up ALK testing using the company's proprietary EML4-ALK RT-PCR-based assay at minimal additional cost.  With the addition of ROS1, ordering clinicians can now make a more complete evaluation of each of their NSCLC patients as candidates for crizotinib therapy.  

1 XALKORI® is a registered trademark of Pfizer, Inc.
2 Bergethon et. al. "ROS1 rearrangements define a unique molecular class of lung cancers." Journal of Clinical Oncology 2012 Mar 10;30(8):863-70. Epub 2012 Jan 3.
3 Ibid

About Response Genetics, Inc. Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic tests for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens.  The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomics testing services of clinical-trial specimens to the pharmaceutical industry.  The Company's headquarters is located in Los Angeles, California.  For more information, please visit www.responsegenetics.com.

Forward-Looking Statement NoticeExcept for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, and to continue to execute on its business strategy and operations, to continue to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law. Investor Relations Contact:

Company Contact:Peter Rahmer

Thomas BolognaTrout Group

Chairman & Chief Executive Officer646-378-2973

323-224-3900


'/>"/>
SOURCE Response Genetics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
2. Response Genetics, Inc. Announces Second Quarter Financial Results
3. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
4. NDIA, NTSA Will Be On Hand At Seventh Annual Capitol Hill Modeling and Simulation Expo, Set To Focus On Homeland Security, First Response
5. Bode Technology Launches Same-Day DNA Service For Faster Response to Law Enforcement and Justice System
6. Covenant Security Services and the Department of Homeland Security Partner to Provide Nationwide Training on Active Shooter Awareness and Response
7. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
8. US Lab Deployed to Boost Mexicos Response to Outbreaks of Infectious Disease
9. Targeted antibacterial agent rapidly created in response to serious food safety pathogen
10. Fukushima 1 year on: Poor planning hampered Fukushima response
11. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 , ... ... custom industrial automation and IT solutions, today announced the company has successfully completed ... delivered professionally executed automation and control systems integration services to leading companies in ...
(Date:12/6/2016)... (PRWEB) , ... December 06, ... ... a Great Point Partners ("GPP") portfolio company, today announced it has acquired ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
(Date:12/6/2016)... DIEGO , Dec. 6, 2016  Creative Medical ... Kesari , MD, PhD, FANA, FAAN to the Company,s ... neurology and clinical trials to assist the Company,s clinical ... stroke. The AmnioStem product is a universal donor stem cell ... activity in animal models of stroke 1 .  ...
(Date:12/6/2016)... MENLO PARK, Calif. , Dec. 6, 2016 ... of up to $150 million from the National ... Infectious Diseases and the Division of AIDS (NIAID-DAIDS) ... microbicides and other non-vaccine pre-exposure (PreP) agents. Under ... suite of preclinical product development services for candidate ...
Breaking Biology Technology:
(Date:11/22/2016)... According to the new market research report "Biometric System Market ... Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region ... to grow from USD 10.74 Billion in 2015 to reach USD 32.73 ... Continue Reading ... ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
Breaking Biology News(10 mins):